JAK2 inhibitors (Merck Research Laboratories Boston)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameJAK2 inhibitors (Merck Research Laboratories Boston)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitors
TargetsTyrosine-protein kinase JAK2
Therapy Area/IndicationsPrimary MyelofibrosisThrombocytosisPolycythemia Vera
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Research Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Research Laboratories
Active IndicationsN/A
Inactive IndicationsPrimary MyelofibrosisThrombocytosisPolycythemia Vera

Other Information

ATC CodeN/A
Related LinksN/A